PURPOSE: EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo. This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a bolus intravenous injection or 1-hour infusion in patients with refractory solid tumors. PATIENTS AND METHODS: EC145 was administered as a bolus injection or 1-hour infusion on days 1, 3, and 5 and days 15, 17, and 19 of each 28-day cycle with dose escalation in cohorts of three to six patients until the MTD was identified. Plasma pharmacokinetics were determined on days 1 and 3 of the first cycle. RESULTS: The MTD of EC145 was 2.5 mg when administered as either a bolus injection or 1-hour infusion. Constipation was the dose-limiting toxicity with both routes. Constipation, nausea, fatigue, and vomiting were the most commonly reported adverse events. One partial response to therapy was observed in a patient with metastatic ovarian cancer. CONCLUSION: EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg on days 1, 3, and 5 and days 15, 17, and 19 of a 28-day cycle has an acceptable safety profile in patients with advanced cancer. On the basis of these findings, phase II studies of EC145 have been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer.
PURPOSE: EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloiddesacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo. This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a bolus intravenous injection or 1-hour infusion in patients with refractory solid tumors. PATIENTS AND METHODS: EC145 was administered as a bolus injection or 1-hour infusion on days 1, 3, and 5 and days 15, 17, and 19 of each 28-day cycle with dose escalation in cohorts of three to six patients until the MTD was identified. Plasma pharmacokinetics were determined on days 1 and 3 of the first cycle. RESULTS: The MTD of EC145 was 2.5 mg when administered as either a bolus injection or 1-hour infusion. Constipation was the dose-limiting toxicity with both routes. Constipation, nausea, fatigue, and vomiting were the most commonly reported adverse events. One partial response to therapy was observed in a patient with metastatic ovarian cancer. CONCLUSION: EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg on days 1, 3, and 5 and days 15, 17, and 19 of a 28-day cycle has an acceptable safety profile in patients with advanced cancer. On the basis of these findings, phase II studies of EC145 have been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Iontcho R Vlahov; Hari Krishna R Santhapuram; Paul J Kleindl; Stephen J Howard; Katheryn M Stanford; Christopher P Leamon Journal: Bioorg Med Chem Lett Date: 2006-07-25 Impact factor: 2.823
Authors: R Wendel Naumann; Robert L Coleman; Robert A Burger; Edward A Sausville; Elzbieta Kutarska; Sharad A Ghamande; Nashat Y Gabrail; Stephen E Depasquale; Elzbieta Nowara; Lucy Gilbert; Robert H Gersh; Michael G Teneriello; Wael A Harb; Panagiotis A Konstantinopoulos; Richard T Penson; James T Symanowski; Chandra D Lovejoy; Christopher P Leamon; David E Morgenstern; Richard A Messmann Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Joseph A Reddy; Elaine Westrick; Iontcho Vlahov; Stephen J Howard; Hari Krishna Santhapuram; Christopher P Leamon Journal: Cancer Chemother Pharmacol Date: 2005-12-06 Impact factor: 3.333
Authors: Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon Journal: Anal Biochem Date: 2005-03-15 Impact factor: 3.365
Authors: Joseph A Reddy; Ryan Dorton; Elaine Westrick; Alicia Dawson; Terri Smith; Le-Cun Xu; Marilynn Vetzel; Paul Kleindl; Iontcho R Vlahov; Christopher P Leamon Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: Chrystal M Paulos; Joseph A Reddy; Christopher P Leamon; Mary Jo Turk; Philip S Low Journal: Mol Pharmacol Date: 2004-09-15 Impact factor: 4.436
Authors: Christopher P Leamon; Joseph A Reddy; Iontcho R Vlahov; Elaine Westrick; Nikki Parker; Jeffrey S Nicoson; Marilynn Vetzel Journal: Int J Cancer Date: 2007-10-01 Impact factor: 7.396
Authors: Steven K Jones; Anwesha Sarkar; Daniel P Feldmann; Peter Hoffmann; Olivia M Merkel Journal: Biomaterials Date: 2017-05-22 Impact factor: 12.479
Authors: Even Walseng; Christopher G Nelson; Junpeng Qi; Alex R Nanna; William R Roush; Rajib K Goswami; Subhash C Sinha; Terrence R Burke; Christoph Rader Journal: J Biol Chem Date: 2016-07-21 Impact factor: 5.157
Authors: Sumith A Kularatne; Vishal Deshmukh; Marco Gymnopoulos; Sandra L Biroc; Jinming Xia; Shaila Srinagesh; Ying Sun; Ning Zou; Mark Shimazu; Jason Pinkstaff; Semsi Ensari; Nick Knudsen; Anthony Manibusan; Jun Axup; Chanhyuk Kim; Vaughn Smider; Tsotne Javahishvili; Peter G Schultz Journal: Angew Chem Int Ed Engl Date: 2013-09-25 Impact factor: 15.336